WorldPing logo WorldPing← All news

STAT+: Pharmalittle: We’re reading about PhRMA suing Trump, biotech frustration over tariffs, and more

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: STAT
STAT+: Pharmalittle: We’re reading about PhRMA suing Trump, biotech frustration over tariffs, and moreWorldPing
Image via STAT.

What happened

PhRMA is suing the Trump administration, smaller biotech firms are frustrated over tariffs, and more of the latest pharma news.

Key facts

  • Reported by STAT and published Thu, 08 Oct 2026 13:15:33 UTC.

Why it matters

Outbreaks, approvals and guidance changes have direct practical consequences for care, travel and public-health planning.

What to watch next

  • Case numbers and official guidance updates
  • Regulatory decisions in other countries
  • Supply, recall or access changes

Coverage timeline

When each newsroom published on this story, oldest first — all times UTC.

  1. STAT+: Biotech companies are struggling to navigate Trump’s new tariffs

  2. STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines

  3. STAT+: Pharmalittle: We’re reading about PhRMA suing Trump, biotech frustration over tariffs, and more

Sources

The original report was published by STAT. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at STAT

Follow the story

Living hubs that keep updating as this story develops.

Related WorldPing coverage

'Death by restriction': As Trump sours H-1B visa dream, who faces biggest hit?WorldPing
Times of India

'Death by restriction': As Trump sours H-1B visa dream, who faces biggest hit?

Three H-1B related changes are stacking on top of each other: the multiple $100,000 fee proposals, the wage-weighted lottery favoring more senior workers, new layoff and compliance scrutiny, and now the OPT/STEM-OPT $70,000 fee proposal for students…

Brief by WorldPing · Original reporting by Times of India